There are benefits of smaller companies teaming up with larger commercial partners to leverage the latter's established sales channels, but the relationship can hit the rocks if the larger partner is having to navigate itself through troubled waters.
This looks to be the case for Respicardia Inc., which suspended an EU post-market study of its remedē neuromodulation system for treating central sleep apnea (CSA) less than six...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?